Houghten Pharmaceuticals Inc. said Thursday it was awarded twoPhase I Small Business Innovation Research grants, which together areworth $135,000.One of the grants will go toward the San Diego company's work inpain, and the other for a study involving infections caused by herpessimplex virus.One award came from the National Institute of Drug Abuse forHoughten to identify highly specific opioid antagonists for thetreatment of intestinal complications caused by long-term use ofmorphine.J. Terrence Greve, Houghten's director, finance and investor relations,said the company's primary focus in terms of clinical strategy is cancerpain, and the work in opioid receptors will synergize some of the workHoughten is doing.The second grant was awarded by the National Institute of Allergy andInfectious Diseases for a study seeking discovery of molecules thatinhibit herpes simplex virus types 1 and 2. The company already hasongoing research in the area of identifying compounds that affect thevirus. _ Jim Shrine

(c) 1997 American Health Consultants. All rights reserved.

No Comments